AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9824790 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 90
Study 9824790 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin plus finasteride
Number of subjects: 90
Study 9824790 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 90
Study 9824790 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin plus finasteride
Number of subjects: 90
Study 9824790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 9824790 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus finasteride
Number of subjects: 90
Study 8013758 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg per os, at -5 and -1 h before the clamp)
Number of subjects: 21
Study 8013758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2786673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g six times per day via gastric tube)
Number of subjects: 32
Study 2786673 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (six 50‐mg to six 100‐mg doses per day intravenously)
Number of subjects: 32
Study 5354877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE(1)) inhalation (triethanolamine salt) at 55 mug
Number of subjects: 6
Study 5354877 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline sulphate inhalation at 550 mug
Number of subjects: 6
Study 5354877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE(1)) inhalation (free acid or neutral triethanolamine salt)
Number of subjects: 6
Study 5354877 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE(1)) inhalation (triethanolamine salt)
Number of subjects: 6
Study 15215066 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-KR interval of 3 seconds
Number of subjects: 90
Study 15215066 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-KR interval of 6 seconds
Number of subjects: 90
Study 15215066 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-KR interval of 12 seconds
Number of subjects: 90
Study 31791008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ending the abusive relationship
Number of subjects: 11
Study 31791008 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety planning strategies
Number of subjects: 11
Study 31791008 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline experiences of IPV
Number of subjects: 11
Study 31791008 — intervention group
Group type: EXPERIMENTAL
Intervention: Final interviews after ending the relationship
Number of subjects: 11
Study 31448013 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard airtime incentive
Number of subjects: 0
Study 31448013 — intervention group
Group type: COMPARATOR
Intervention: Double airtime incentive
Number of subjects: 0
Study 31448013 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard reminder
Number of subjects: 0
Study 31448013 — intervention group
Group type: COMPARATOR
Intervention: Daily follow-up reminder
Number of subjects: 0
Study 31448013 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivised mHealth solution
Number of subjects: 0
Study 28735755 — intervention group
Group type: EXPERIMENTAL
Intervention: 30min of vigorous‐intensity exercise 24h prior to the first doxorubicin treatment
Number of subjects: 24
Study 28735755 — intervention group
Group type: COMPARATOR
Intervention: No vigorous exercise for 72h prior to treatment (control)
Number of subjects: 24
Study 25896256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine challenge during a 55-minute resting-state scan
Number of subjects: 30
Study 25896256 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study 24379055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed oral combination of hyaluronic acid and chondroitin-sulphate (HA+CS)
Number of subjects: 20
Study 24379055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21457209 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene-benzoyl peroxide gel
Number of subjects: 243
Study 21457209 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 243
Study 19598021 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 191
Study 19598021 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 191
Study 17639559 — intervention group
Group type: EXPERIMENTAL
Intervention: Slim339 (Garcinia cambogia extract with calcium pantothenate and herbal extracts)
Number of subjects: 58
Study 17639559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15851216 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced detection in dual-chamber ICD
Number of subjects: 149
Study 15851216 — intervention group
Group type: COMPARATOR
Intervention: Control (rate-only detection)
Number of subjects: 149
Study 11468265 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine testing before cataract surgery
Number of subjects: 0
Study 11468265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal occult bleed testing
Number of subjects: 0
Study 9770086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 387
Study 9770086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 8093148 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced education programme (four personalised booklets, sent by post)
Number of subjects: 801
Study 8093148 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional oral education at outpatient or surgery visits)
Number of subjects: 801
Study 3065411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium intervention directed at women through mass media techniques
Number of subjects: 2211
Study 3065411 — intervention group
Group type: COMPARATOR
Intervention: Control town (observed without intervention)
Number of subjects: 2211
Study 3065411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium intervention directed at men
Number of subjects: 2211
Study 31189406 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Number of subjects: 0
Study 28826348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer-based intervention
Number of subjects: 32
Study 26049672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (coaches attended 2 coach education sessions)
Number of subjects: 76
Study 23864141 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CM) added to methotrexate (MTX) and methylprednisolone (MP)
Number of subjects: 32
Study 23864141 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) and methylprednisolone (MP) alone
Number of subjects: 32
Study 21600570 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention to reduce stress
Number of subjects: 16
Study 21600570 — intervention group
Group type: COMPARATOR
Intervention: High stress group (n = 8)
Number of subjects: 16
Study 21600570 — intervention group
Group type: EXPERIMENTAL
Intervention: Low stress group (n = 8)
Number of subjects: 16
Study 21600570 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful events correlated with elevated levels of MDSC
Number of subjects: 16
Study 19195510 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (TAXUS)
Number of subjects: 531
Study 19195510 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMSs)
Number of subjects: 531
Study 19195510 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual edge plaque burden
Number of subjects: 531
Study 16987347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg intravenously
Number of subjects: 80
Study 16987347 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 15190232 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 36
Study 15190232 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT analysis using [123I]‐FP‐CIT
Number of subjects: 36
Study 10357732 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched diet (1.7 g phytosterols/d for 30 d)
Number of subjects: 32
Study 10357732 — intervention group
Group type: COMPARATOR
Intervention: Control diet (prepared foods alone)
Number of subjects: 32
Study 10357732 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched diet
Number of subjects: 32
Study 10357732 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 32
Study 8952863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin administration with tissue plasminogen activator
Number of subjects: 0
Study 8952863 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous or intravenous heparin use with streptokinase
Number of subjects: 0
Study 8952863 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining aPTT in the 55‐70 second range
Number of subjects: 0
Study 2010166 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized 355 kcal mixed‐liquid meal
Number of subjects: 24
Study 2010166 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study 6125205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine 200 mg or 400 mg
Number of subjects: 0
Study 6125205 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule preparations of diazepam
Number of subjects: 0
Study 30394805 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon for 1 month
Number of subjects: 450
Study 30394805 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon for 3 months
Number of subjects: 450
Study 30489516 — intervention group
Group type: EXPERIMENTAL
Intervention: EB-001
Number of subjects: 42
Study 30489516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 26599796 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline flush (20 mL normal saline) after rocuronium administration
Number of subjects: 48
Study 24271264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (CT, n = 61)
Number of subjects: 122
Study 24271264 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (SC, n = 61)
Number of subjects: 122
Study 24271264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study 22388610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic exercise (15 min/d, 3 times a week for 8 weeks)
Number of subjects: 47
Study 22388610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 47
Study 20400266 — intervention group
Group type: EXPERIMENTAL
Intervention: Quebec Back Pain Disability Scale (administered pre-treatment and post-treatment)
Number of subjects: 212
Study 20400266 — intervention group
Group type: EXPERIMENTAL
Intervention: Quebec Back Pain Disability Scale score change expressed in percentage
Number of subjects: 212
Study 18385466 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food (300 kcal) and water ad libitum
Number of subjects: 16
Study 15529306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐radiation dose spiral computed tomography (LDCT)
Number of subjects: 1660
Study 15529306 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray
Number of subjects: 1660
Study 12457268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (via ingestion of a mixture of essential amino acids excluding tryptophan)
Number of subjects: 24
Study 10499652 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n = 10): standard heparinization (300 IU/kg) plus two doses of purified antithrombin III (1000 IU each)
Number of subjects: 30
Study 10499652 — intervention group
Group type: EXPERIMENTAL
Intervention: Group GA (n = 10): 200 IU/kg heparin, continuous infusion of heparin (100 IU/kg/h) and gabexate mesilate (2 mg/kg/h) plus the same dose of antithrombin III as group A
Number of subjects: 30
Study 10499652 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n = 10): standard heparinization (300 IU/kg)
Number of subjects: 30
Study 7573999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (50 micrograms.kg‐1.min‐1)
Number of subjects: 7
Study 7573999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2019163 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 percent phenylephrine
Number of subjects: 107
Study 2019163 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 percent lidocaine
Number of subjects: 107
Study 2019163 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 percent phenylephrine + 4 percent lidocaine
Number of subjects: 107
Study 2019163 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percent cocaine
Number of subjects: 107
Study 2019163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 2019163 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 percent phenylephrine + Placebo
Number of subjects: 107
Study 2019163 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percent cocaine + Placebo
Number of subjects: 107
Study 2019163 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 percent viscous lidocaine (sniffed)
Number of subjects: 107
Study 6818588 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg nicotine cigarettes
Number of subjects: 0
Study 6818588 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg nicotine cigarettes
Number of subjects: 0
Study 31725087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy‐based navigated guidance of lag screw length and position
Number of subjects: 31
Study 31725087 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 31
Study 30286625 — intervention group
Group type: EXPERIMENTAL
Intervention: On-Pump Coronary Artery Bypass (ONCAB)
Number of subjects: 308
Study 30286625 — intervention group
Group type: COMPARATOR
Intervention: Off-Pump Coronary Artery Bypass (OPCAB)
Number of subjects: 308
Study 29089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™, Elanco) at 20 mg/kg
Number of subjects: 111
Study 29089063 — intervention group
Group type: COMPARATOR
Intervention: Afoxolaner (Nexgard®, Merial) at 2.5 mg/kg
Number of subjects: 111
Study 29089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 111
Study 29089063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner
Number of subjects: 111
Study 26981577 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phage therapy (T4-like coliphages or commercial Russian coliphage product)
Number of subjects: 120
Study 26981577 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phage therapy
Number of subjects: 120
Study 26981577 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 120
Study 25066269 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (10 mg/kg, intravenous) with mFOLFOX6
Number of subjects: 148
Study 25066269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose linifanib (7.5 mg) with mFOLFOX6
Number of subjects: 148
Study 25066269 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose linifanib (12.5 mg) with mFOLFOX6
Number of subjects: 148
Study 22199189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill (OCP)
Number of subjects: 27
Study 22199189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 20845988 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cell-free DNA
Number of subjects: 360
Study 18057338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin (2 mg daily subcutaneous injection for 26 weeks)
Number of subjects: 412
Study 18057338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 412
Study 15638875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 30
Study 15638875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12105323 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (400 mg/d or maximum tolerated dose)
Number of subjects: 24
Study 12105323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10427867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen indices (P(A‐a)O2, PaO2/FiO2, PaO2/PAO2, P(A‐a)O2/PaO2) after FiO2 modifications
Number of subjects: 50
Study 10427867 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2‐required formula to obtain desired PaO2
Number of subjects: 50
Study 1391977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 92
Study 1391977 — intervention group
Group type: COMPARATOR
Intervention: No hormone treatment (Control)
Number of subjects: 92
Study 1391977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (in premenopausal women)
Number of subjects: 92
Study 3999081 — intervention group
Group type: EXPERIMENTAL
Intervention: Diumide‐K Continus tablets
Number of subjects: 30
Study 3999081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasikal tablets
Number of subjects: 30
Study 3999081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasix and Slow‐K tablets
Number of subjects: 30
Study 30381244 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-enriched light (high intensity of ca. 1000 lx, short duration: <1 h)
Number of subjects: 0
Study 30381244 — intervention group
Group type: COMPARATOR
Intervention: Red-enriched light
Number of subjects: 0
Study 29364579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional protein-rich drink
Number of subjects: 0
Study 29364579 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 0
Study 29364579 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 0
Study 26525831 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygen concentration (100%)
Number of subjects: 52
Study 26525831 — intervention group
Group type: COMPARATOR
Intervention: Mild oxygen concentration (60%)
Number of subjects: 52
Study 26525831 — intervention group
Group type: COMPARATOR
Intervention: Low oxygen concentration (40%)
Number of subjects: 52
Study 26696093 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 26696093 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group) cultured with GM-CSF or M-CSF
Number of subjects: 0
Study 26696093 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 24013592 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal representations of novel rewards constructed by invoking multiple independent memories in hippocampus and medial prefrontal cortex
Number of subjects: 0
Study 24013592 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging repetition suppression
Number of subjects: 0
Study 20501982 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (n = 20)
Number of subjects: 35
Study 20501982 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 15)
Number of subjects: 35
Study 18309618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chairside airborne particle abrasion with 50-microm Al2O2 + Alloy Primer (Kuraray)
Number of subjects: 40
Study 18309618 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne particle abrasion with 50-microm Al2O3 + Cesead II Opaque Primer (Kuraray)
Number of subjects: 40
Study 18309618 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne particle abrasion with 50-microm Al2O3 + Silano-Pen + silane coupling agent (Bredent)
Number of subjects: 40
Study 18309618 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tribochemical silica coating (110-microm Al2O3 + 110-microm SiOx) (Rocatec) + silane coupling agent (ESPE-Sil)
Number of subjects: 40
Study 16543099 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 164
Study 16543099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 12655908 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone or nefazodone
Number of subjects: 147
Study 12655908 — intervention group
Group type: COMPARATOR
Intervention: Other antidepressant drugs
Number of subjects: 147
Study 12655908 — intervention group
Group type: COMPARATOR
Intervention: Nonteratogenic drugs
Number of subjects: 147
Study 10984014 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine syrup 3.5%
Number of subjects: 200
Study 10984014 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine sachets 225 mg
Number of subjects: 200
Study 10984014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for syrup 3.5%)
Number of subjects: 200
Study 10984014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for sachets 225 mg)
Number of subjects: 200
Study 9475311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid aspartate levels in patients with infantile spasms
Number of subjects: 13
Study 9475311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid glutamate levels in patients with infantile spasms
Number of subjects: 13
Study 8014172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-mineral supplementation
Number of subjects: 0
Study 8014172 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3236320 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg/day)
Number of subjects: 10
Study 3236320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28892237 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation with relaxation
Number of subjects: 250
Study 28892237 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency cesarean delivery
Number of subjects: 250
Study 28892237 — intervention group
Group type: COMPARATOR
Intervention: Partners of women with severe FOC
Number of subjects: 250
Study 28277692 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making with a random device for allocation of rewards
Number of subjects: 0
Study 28277692 — intervention group
Group type: COMPARATOR
Intervention: Decision-making without a random device for allocation of rewards
Number of subjects: 0
Study 23774275 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-derived alpha-linolenic acid (ALA) 2g/day
Number of subjects: 2425
Study 23774275 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 400mg/day
Number of subjects: 2425